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Summary
Systemic infusion of low concentrations of tumor necrosis factor/cachectin (TNF)into mice that
bear TNF-sensitive tumors leads to activation of coagulation, fibrin formation, and occlusive
thrombosis exclusively within the tumor vascular bed. To identify mechanisms underlying the
localization of this vascular procoagulant response, a tumor-derived polypeptide has been purified
to homogeneity from supernatants of murine methylcholanthrene A-induced fibrosarcomas that
induces endothelial tissue factor synthesis and expression (half-maximal response at -300 pM),
and augments the procoagulant response to TNF in a synergistic fashion. This tumor-derived
polypeptide was identified as the murine homologue ofvascular permeability factor (VPF) based
on similar mobility on SDS-PAGE, an homologous NH2-terminal amino acid sequence, and
recognition by a monospecific antibody to guinea pig VPF. In addition, VPF was shown to
induce monocyte activation, as evidenced by expression of tissue factor. Finally, VPF was shown
to induce monocyte chemotaxis across collagen membranes and endothelial cell monolayers. Taken
together, these results indicate that VPF can modulate the coagulant properties of endothelium
and monocytes, and can promote monocyte migration into the tumor bed. This suggests one
mechanism through which tumor-derived mediators can alter properties of the vessel wall.
Tumor vasculature, derived from the ingrowth of normal
vessels, is in continuouscontact with host mediators and
metabolic/regulatory products of the tumor. Since the en-
dothelium is the actual interface between host and tumor,
studies into the properties of tumor vascular endothelium
provide insights into the effects of local factors on vascular
function. One striking example of the altered responsiveness
of tumor vasculature is observed after the systemic infusion
of a low concentration of tumor necrosis factor/cachectin
(TNF) into mice that bear TNF-sensitive tumors, such as
methylcholanthrene A-induced fibrosarcomas (meth A sar-
comas)' (1-3). Under these conditions, intravascular fibrin
deposition, progressing to occlusive thrombosis and associated
with a fall in blood flow, is observed in tumor vessels, but
not in the normal vessels. An important potential mecha-
1 Abbreviations used in this paper. bFGF, basic fibroblast growth factor; meth
A sarcomas, methylcholanthrene A-induced fibrosarcomas; VEGF, vascular
endothelial growth factor; VPF, vascular permeability factor.
nism through which TNF can initiate this localized throm-
botic process involves enhanced focalinduction of endothelial
synthesis and expression of tissue factor, a cell surface pro-
coagulant cofactor (4-6). Tissue factor is believed to be the
major initiator of coagulation in vivo (6).
To understand mechanisms that could account for selec-
tive or enhanced induction of tissue factor in endothelium
of tumor vasculature, we have examined the role of tumor-
derived mediators. The results indicate that cultured meth
A sarcoma cells elaborate at least two distinct polypeptides
that induce tissue factor in endothelium and enhance the
procoagulant response to TNF. In a previous report (7), we
described the properties ofone of these polypeptides, referred
to as meth A factor. This report describes the second of these
proteins. The biochemical properties, NH2-terminal sequence,
and reactivity with monospecific antisera indicate that this
second tumor-derived polypeptide is the murine homologue
ofvascular permeability factor (VPF) (8), a protein previously
shown to promote endothelial growth and angiogenesis, as
1535
￿
J. Exp. Med. ® The Rockefeller University Press " 0022-1007/90/12/1535/11 $2.00
Volume 172 December 1990 1535-1545well as vascular leakage(9). VPF is closely related, ifnot iden-
tical, to vascular endothelial growth factor (VEGF) (10-12).
Murine VPF is also shownhere to stimulate tissue factor ex-
pression in monocytes, and to cause monocyte chemotaxis,
through collagen membranesand through endothelial mono-
layers. These findings suggest that tumor-derived VPF can
modulate the vascular procoagulant response to TNF. Fur-
thermore, theseresults suggest that VPF could attract mono-
cytes to the tumor bed where they, in turn, could further
promote activation of coagulation and contribute to fibrin
deposition.
Materials and Methods
Cell Culture andAssays.
￿
Humanumbilicalvein endothelial cells
were preparedby themethod ofJaffe(13), as modified by Thornton
et al. (14). Experiments were carried out within 48 h of the cells
achieving confluence, andcultures were characterized as described
previously (7). Meth Acells, provided by Drs. Hoffman and Old
(Memorial Sloan-Kettering Cancer Center, New York) (15), were
grown in RPMI 1640 containing 10% calf serum, as previously
described (7, 16). In brief, they were immobilized in a continu-
ouslyperfused 3-liter bioreactor (Bellco Glass, Inc., Vineland, NJ).
Conditioned serum-free medium was collected from thebioreactor
at a rate of 416 ml/h, and concentrated 20-fold by ultrafiltration
before purification.
Expression of tissue factor in endothelial cells was assessed by
incubating cultures with column fractions or purified VPF in
medium 199 containing 10 mM Hepes (pH 7.4), polymyxin B
(1 Wg/ml) in the presence/absence of TNF, antibodies, or other
reagents (e.g., cycloheximide). These studies were carried out in
35-mm diameter wells with -1.2 x 105 cells/cm2 at confluence.
Samples of murine or guinea pig VPFwere incubated with either
endothelium alone or in the presence of human rTNF for 6 h (or
for theindicated times) at 37°C. Assays were carriedoutwith whole
cells obtained in suspension after scraping from the dish with a
rubber policeman (cell viability was >90% based on trypan blue
exclusion) or on intact monolayers. Tissue factor activity was de-
termined by a two-stage coagulant assay and, in alimited number
of experiments, by measuring the formation of factor Xa in the
presence of purified factor VIIa (8 nM) and X (1.5 p.M) using a
synthetic substrateassay to assess factor Xa formation, as described
previously (17). Further characterization ofendothelial procoagulant
activity included preincubation of cultures with ablocking mAb
to human tissue factor (5 wg/ml) (18) for 30 min at 37°C before
carrying outthetissue factor assay(eithercoagulantor amidolytic).
Tissue factor equivalents were determined by usingastandardcurve
of purified humantissue factor (19). To constructthestandard curve,
tissue factor wasreconstituted into phosphatidylserine/phosphati-
dylchohne vesicles (20:80) (19), and factor Xa formation was de-
termined by the two-stagecoagulant assay. Purified human tissue
factor reconstituted into phospholipid vesicles and blocking mAb
to human tissue factor was generously provided by Dr. R. Bach
(Mt. Sinai School of Medicine, New York) (18, 19).
Human monocytes were isolated from the mononuclear frac-
tion of peripheral blood by a discontinuous Ficoll gradient (histo-
paque 1077; Sigma Chemical Co., St. Louis, MO) using gradient
centrifugation with Percoll (Sigma Chemical Co.), as describedby
Fluks (20). Monocyte preparations were assessed morphologically
with Wright's stain (>90), and theirviability was >90% by trypan
blue exclusion. Induction of monocyte tissue factor was studied
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by incubating the cells (105/assay) for 6 h at 37°C in RPMI 1640
containing 10 mM Hepes, pH 7.4, penicillin, streptomycin (50
U/ml; 50 Fg/ml), polymyxinB(5 htg/ml), andautologous serum
(10%) in thepresence ofvaryingconcentrations of VPF or other
factors. Tissue factor was determined as described above, and the
same protocol was followed with the antibody to tissue factor.
Chemotaxis of monocytes and otherperipheral bloodcells was
investigated using the method of Quinn et al. (21). Briefly, cells
isolated as described abovewere placed in the upper chamber, and
a test substance wasplaced in thelowerchamber. In certain experi-
ments, mediators were also placed in the upper chamber. Chemo-
tactic assays were performed after 3 h of incubation, and cells in
10 fields were counted for each condition assayed. Chemotaxis of
monocytes across endothelial monolayers was studied by growing
endothelium to confluence on Cellagen (ICN Biomedicals, Costa
Mesa, CA), and VPF was placed in the outer (lower) well. At the
end of the incubation period, monolayers were fixed for electron
microscopy in glutaraldehyde (2.5%)/sodium cacodylate (0.1 M,
pH 7.2), post-fixed in osmium tetroxide (2%), washed, en bloc
stainedin uranyl acetate (0.5%), dehydrated in ethanol, andembed-
dedin Epon 812. Sections were observed in an electron microscope
(model 300; Philips Electronic Instruments, Inc., Mahwah, NJ).
Purification ofVPF andOtherReagents.
￿
Murine VPF waspurified
from serum-free medium conditioned by cultured meth A cellsby
sequential chromatography on S-Sepharose, Mono S, FPLC and
reversed-phase HPLC (C4). Conditioned medium was acidifiedto
pH 5.5 with hydrochloric acid, diluted 1:1 with 50 mM MES(pH
5.5), andapplied to thecation exchange resin S-Sepharose Fast Flow
(5 ml resin/liter) (Pharmacia Fine Chemicals, Piscataway, NJ). The
resin was washed extensively in buffer containing MES (50 mM;
pH 5.5), NaCl (50mM), octyl-/3-glucoside (0.1%), andPMSF (0.2
mM), and step-eluted with thesame buffer containing 1 M NaCl.
Fractions with ODno >0.05 were pooled and dialyzed extensively
against phosphate buffer (50 mM; pH 5.5) containing NaCl (50
mM) and octyl-/3-glucoside (0.1%). These procedures were per-
formed at 4°C. Thepool from Fast Swas then applied to a Mono
SFPLC column (HR5/5;PharmaciaFine Chemicals) equilibrated
in thesame buffer. Thecolumn waseluted with an ascending salt
gradient (0-1 M NaCl), the active fractions were pooled, the pH
was adjusted to 2.2 with trifluoroacetic acid, and the sample was
applied to areversed-phase HPLC column (C4 reversed phase; 4.6
x 20 mm, Supellco,Inc., Bellefonte, PA). Thecolumn waseluted
with a linear acetonitrile gradient (0-100%), aliquots of the frac-
tions were concentrated by lyophilization, and then processed as
follows. To assess tissue factor inducing activity, sampleswere solu-
bilizedin endothelial cell culture medium (see above), andforSDS-
PAGE according to themethod ofLaemmli (22), sampleswere solu-
bilizedin sample buffer. To elute samples from SDS-PAGE,gel slices
(0.5 cm) were incubated in elution buffer (Tris/HCI, 0.1 M, pH
7.5; NaCl, 0.3 M; EDTA, 2 mM; octyl-a-glucoside, 0.2%; BSA,
0.1 mg/ml) with agitation overnight at 4°C. Samples were cen-
trifuged, and aliquots of the supernatants were tested for tissue
factor-inducing activity on endothelial monolayers as described.
For sequence analysis, purified murine VPF was subjected to re-
duced SDS-PAGE, transferred to polyvinylidene difluoride mem-
branes, by the method of Matsudaira (23), and the band corre-
sponding to M -23,000 was cut out and sequenced (model
470A; Applied Biosystems, Inc., Foster City, CA).
Purified guinea pig VPF and monospecific blocking antibody
to guinea pig VPF (made in a rabbit) were prepared as described
previously (10). Immunoadsorption ofVPF wasaccomplished using
the IgG fraction of the antiVPF antiserum bound to protein
A-Sepharose (Pharmacia Fine Chemicals), as describedin thelegendto Fig . 4 . In pilot studies, each VPF-containing sample was always
adsorbed at least twice to protein A-coated beads with adsorbed
antiVPF IgG to be certain that maximum removal ofVPF had
been accomplished . Murine meth A factor was also prepared by
a previously described procedure (7) . Purified, human rTNF-a
(-10 8 U/mg) was generously provided byDr. P. Lomedico, Hoff
man-La Roche, Inc., Nutley, NJ .
Results
Purification of a -46 kD Polypeptide from Murine meth A
Sarcoma Cells thatInduces EndothelialProcoagulantActivity . The
localized vascular response that follows systemic infusion of
low concentrations of TNF into mice that bear meth A
fibrosarcomas could result, at least in part, from the con-
certed action of tumor-derived mediators and TNF acting
on the endothelial cell . In a previous study, a polypeptide
factor of Mr -56,000 on reduced SDS-PAGE (meth A
factor), isolated from cultured methA fibrosarcoma cells, in-
duced endothelial tissue factor and enhanced the procoagulant
response to TNF (7) . During the course of these studies, an-
other mediator, distinct from meth A factor, was identified
in the conditionedmedium of meth A cells, which was also
Figure 1 .
￿
Chromatography of partially purified meth A-conditioned
medium on heparin-ultragel . Meth A-conditioned medium was subjected
to batch adsorption on S-Sepharose (as described in the text), step eluted
with 1 M NaCl, dialyzed against phosphate (50 mM; pH 7.4), and then
applied to heparin-ultragel . The heparin column was eluted with an
ascending salt gradient (0-2M NaCl), and fractionswere assayed for their
ability to induce tissuefactor activity in endothelial cells as described . The
two separated peaks ofactivity (I and II) are indicated with arrows. (Inset)
Procoagulant inducing activity peak I from the heparin column was pooled,
and subjected to further purification using the procedure previously de-
scribed for methA factor (see text) . (Lane 1) Purified meth A factor on
reduced ; (lane 2) nonreduced SDS-PAGE . Arrowheads indicate migration
of standard proteins run simultaneously: phosphorylase (90 kD), albumin
(68 kD), OVA (45 W), and carbonic anhydrase (30 kD) .
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a potent inducer of endothelial procoagulant activity (which
has been characterized as tissue factor, see below), and is the
subject of this report.
After batch adsorption and elution of serum-freemedium
conditioned by meth A cells from S-Sepharose chromatog-
raphy on heparin-ultragel separated the procoagulant-inducing
activity into two pools (Fig. 1) : activity I eluted at -0.15
M NaCl, whereas activity II required -0.8MNaCl for elu-
tion . Using our previously described procedure (7), methA
factor was purified from the low salt pool (Fig. 1, inset) . The
material in the second activity peak with higher affinity for
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Figure 2 .
￿
Purification ofmurine VPF from meth A-conditioned medium.
(A) Chromatography ofmeth A-conditioned medium on MonoA . Meth
A-conditioned medium was prepared for chromatography on Mono S as
described in the text, and the column was eluted with ascending salt gra-
dient (0-1M NaCI). Tissue factor activity induced in endothelial cell cul-
tures was assayed after a 6-h incubation with aliquots from each fraction .
(B) Chromatography on reversed-phaseHPLC . Thepool of fractions con-
taining peak procoagulant-inducing activity from the Mono S columnwas
applied to a reversed-phase C4 column (4 .6 x 20 mm) in the presence
of 0.1% trifluoroacetic acid and eluted with an ascending acetonitrile gra-
dient (0-50%) . Tissue factor activity induced in endothelial cultures was
assayed as described in the text and in A . Peak activity eluted at an acetoni-
trile concentration of -38% . The mean of duplicate determinations of
tissue factor activity is shown in A and B (only the results of peak frac-
tions are shown) .Depicted is the purification of 10 liters of meth A conditioned by sequential batch adsorption to S-Sepharose, Mono S FPLC, and reversed-phase
HPLC, as described in the text .
' Total activity denotes tissue factor activity induced in the endothelium by column fractions after a 6-h incubation period . Thenumbers represent
picograms of tissue factor induced in the endothelium per 106 cells .
t Tissue factor induction due to VPF (neutralized VPF activity) was determined by adsorption of samples with immobilized anti-VPF IgG, as described
in the text .
5 Neutralized VPF activity divided by the amount of protein (milligrams) .
immobilized heparin was studied in detail . First, tumor-
conditioned medium was subjected to sequential chromatog-
raphy on cation exchange resins, first by batch adsorption
on Fast S and then, after dialysis, on Mono S FPLC . This
led to the identification of a major peak of endothelial
procoagulant-inducing activity that eluted at 0.5 M NaCI
from Mono S (Fig. 2 A), and proved to have an affinity for
heparin comparable with activity pool II from the heparin
ultragel column in Fig . 1 . The otherpeak of activity, which
eluted at 0.3 M, was thepreviously identified methA factor
and corresponded to activity peak I from the heparin-ultragel
column (Fig . 1) . The material that eluted at a higher salt
concentration from theMonoScolumnwaspooled and sub-
jected to reversed-phase HPLC chromatography (C4), eluting
at an acetonitrile concentration ofx+38% (Fig . 2 B) . Using
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the sequence of steps outlined above, -2.5 x 104-fold pur-
ification was obtained with a yield of -17% (see Table 1) .
When fractionswith peak activity from the reversed-phase
column were subjected to SDS-PAGE, a single major band
was observed under reducing conditions with M, corre-
sponding to -23 kD (Fig. 3 a) . Elution of material from
the gel using the same sample prepared underreducing con-
ditions, but not subjectedto the fixation and staining proce-
dure, produced a peak of endothelial procoagulant inducing
activity (Fig. 3 b) that comigrated with the -23-kD band.
Thus, even after reduction, activity was retained by the purified
polypeptide, probably consequent on refolding of the pro-
tein during the incubation in nondenaturing buffer after gel
elution. Nonreduced, the same sample applied to in Fig . 3
a migrated as a single band, withM r corresponding to -46
Figure 3.
￿
SDS-PAGE (12.5%) and gel elu-
tion ofmurine VPF. (a) Reduced SDS-PAGE
of purified murine VPF (after reversed-phase
chromatography) visualized by silver staining.
(b) Activity profile ofmaterial eluted from the
indicated slice ofa reducedSDS gel run identi-
cally as in a (see text) . Data are expressed as
tissue factor equivalents, as described in the text .
(c) Nonreduced SDS-PAGE ofpurifiedmurine
VPF visualized by silver staining. (d) Elution
of tissue factor-inducing activity from slices
of the nonreduced SDS gel corresponding to
c . The mean of duplicate determinations are
shown . Apparent molecular weights, shown
by the arrows, were interpolated from semi-
logarithmic plots based on the migration of
standard proteins run simultaneously (phos-
phorylase, 90,000; BSA, 68,000;OVA, 45,000 ;
carbonic anhydrase, 30,000; trypsin inhibitor,
20,000; lysozyme, 14,000).
Table 1. Purification of Murine
Step
VPF
Protein Total activity"
Neutralized
VPF activity# Yield
Specific
VPF activitys
Purification
for each step
mg x 103 x 103 % x 10' fold
Meth A-conditioned medium 800.00 1,200 750 100 0.9 1.0
S-Sepharose 180.00 980 412 55 2.3 2 .4
Mono S 2.00 340 338 45 169 73.5
Reversed-phase 0.005 125 125 17 25,000 148.0kD (Fig. 3 c) . Elution of material from nonreduced samples
identical to those applied in Fig . 3 c demonstrated that the
peak of procoagulant-inducing activity had also migrated in
parallel with the -46-kD band (Fig. 3 d) .
Further properties of the tumor-derived -46-kD polypep-
tide included resistance to heat (98°C for 10 min) and acidic
conditions (pH 2.0 for 1 h), but sensitivity to protease treat-
ment (protease K, 0.4 ng/10 ng substrate for 2 h at 37°C) .
Although this material could induce procoagulant activity
in endothelium, it had no direct, intrinsic ability to shorten
the clotting time of recalcified plasma (data not shown) .
Identification oftheMurine methA Sarcoma-derived ti46-kD
Polypeptide as the Murine Homologue ofVPF . VPF is a poly-
peptide mediator produced constitutively by certain tumor
cells and cell lines, e.g., guinea pig line 10 cells, bovine pitu-
itary cells, and human U937 cells (8-12), that increases vas-
cular permeability and stimulates endothelial proliferation .
On SDS-PAGE, VPF migrates with M r "34,000-46,000
nonreduced and "18,000-23,000 reduced, similar to the poly-
peptide isolated from the meth A cells described in Figs . 1
and 2. Furthermore, VPF has been reported to have an affinity
for immobilized heparin comparable with that observed for
activity II in Fig . 1 (10) . Based on these findings, it seemed
possible that the murine N46-kD polypeptide with higher
affinity for heparin was similar to VPF.
NHz-terminal sequence analysis showed that five of the
first seven residues of the murine ti46kD polypeptide were
identical to that reported for guinea pig VPR The sequence
of the murine -46 kD factor was Ala-ProThrThr-Glu-Gly-
Glu, whereas the sequence ofguinea pigVPF (8) is Ala-Pro-
MetAla-Glu-Gly-Glu (in the case ofbovine VPF/VEGF, four
of the first seven residues are identical) (12) .
The identity of the 46-kD polypeptide with VPF was
confirmed using a monospecific, neutralizing antibody to
guinea pig VPR Fig. 4 A shows that anti-guinea pig IgG
could quantitatively prevent induction of endothelial tissue
factor by the murine N46-kD polypeptide, coincident with
immunoadsorption of this polypeptide from samples (data
not shown) . The anti-VPF IgG did not interact with the pre-
viously described methA factor (7), confirming our impres-
sion thatVPF and methA factor are distinct . Furthermore,
purified guinea pig VPF also induced procoagulant activity
in endothelium (Fig. 4 A) . Taken together, these data indi-
cate that the murine ti46-kD polypeptide with high affinity
for heparin derived frommeth A sarcoma cells is most likely
the murine homologue of VPF (termed murine VPF) .
The procoagulant activity induced by VPF in the en-
dothelium was identified as tissue factor, based on its inhibi-
tion when cultures were pre-incubated with a neutralizing
antibody to tissue factor (Fig. 4 B) .
Modulation of Endothelial Cell Procoagulant Activity by
VPF . When purified murine or guinea pig VPF was in-
cubated with endothelial cultures, induction of tissue factor
activity occurred in a time-dependentmanner (Fig. 5, insets) .
Cellular procoagulant activity was detectableby 4 h of incu-
bation, maximal by 6-9 h, and began to fall off by 10 h after
the exposure to either purified murine or guinea pig VPF.
Expression of tissue factor in response to VPF resulted from
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Figure 4 .
￿
Effect of VPF and antibody to VPF on endothelial cell tissue
factor activity. (A) Induction ofendothelial tissue factor by VPF. Murine
VPF (5 ng/ml) or guinea pig VPF (5 ng/ml) was incubated with poly-
clonal IgG to VPF (antiVPF; 10 kg) or nonimmune IgG (10 Rg/ml) ad-
sorbed to protein A-Sepharose (0 .1 ml), and the resin was removed by
centrifugation . Samples were thenincubated with endothelialmonolayers
for 6 h at 37°C, and tissue factor activity was assessed as described in
the text . The mean oftriplicate determinations is shown . (B) Identification
of the endothelial procoagulant activity induced by VPF as tissue factor.
Murine VPF (5 ng/ml) or guinea pig VPF (VPF; 5 ng/ml) was incubated
with endothelial monolayers for 6 h at 37°C, and then after washing the
cultures, anti-tissue factor IgG (anti-TF IgG ; 5 Fig/ml) or the sameamount
of nonimmune IgGwas incubatedwith the cultures under serum-freecon-
ditions for 30 min at 37°C. Then, tissue factor activity was assessed as
describedin the text . The mean ± SD oftriplicatedeterminations is shown .
For certain points, where error bars are difficult to see, the errorwas smaller
than the symbol size .
de novo protein synthesis as indicated by inhibition in the
presence of cycloheximide. When TNF was present along
withVPF in the incubation mixture, tissue factor expression
was enhanced at each time point after 2 h . Induction of en-
dothelial tissue factor by murine VPF also depended on the
concentration of mediator, being half-maximal at -300pM,
and maximal by til nM (Fig. 5, A and B) . This is some-
what higher than the half-maximal concentration of VPF
reported for stimulation ofendothelial growth (60-100 pM),
although it is lower than levels ofVPF that increase vascular
permeability in vivo (8-12) . When endothelial cells were in-
cubated with VPF and TNF, induction of tissue factor by
the two agents was greater than that observed with either
agent alone, and appeared to be more than additive . Further-
more, in the presence of TNF (5 pM), the concentration
of VPF required for the half-maximal response decreased
to -150 pM with murine VPF and -90 pM with guinea
pig VPF.
Since in in vivo situations endothelium is likely to be ex-
posed to several tumor-derived mediators over longer times,
it was important to examine the combined effects ofVPF
and meth A factor in the presence and absence of TNR For
these experiments, endothelial cells were pre-incubated with
one mediator for 24 h (VPF or meth A factor), and then
the second mediator was added with or without TNF for
an additional 6 h (Fig. 6) . Because of this difference in incu-
bation times between the experiments in Fig. 6 and Fig. 5,
A andB (in the latter the total incubation time was only
6 h), the absolute amount of tissue factor induced in en-
dothelium in thetwo experiments is not closely comparable .This was expected from the time course of tissue factor ex-
pression induced by VPF (Fig. 5, insets). When endothelium
was preincubated with a low concentration of either VPF
or meth A factor alone, induction of tissue factor activity
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Figure 5.
￿
Dose dependence and time
course of endothelial cell tissue factor
induction by murine VPF and guinea
pig VPP. Endothelial monolayers were
incubated for 6 h at 37°C with the in-
dicated concentrations ofeither murine
VPF (A) or guinea pig VPF (B) either
alone (dotted line) or in the presence of
TNF (5 pM; solid line). When en-
dothelial cells were incubated under the
sameconditions with TNF alone(5 pM),
-40 pg of tissue factor per 106 cells
was induced (Insets) Time course for in-
duction of tissue factor by VPP. (Inset
A) Purified VPF (200 plat) was in-
cubated for theindicated times with en-
dothelial monolayen either alone(filled
circles) or in thepresence ofTNF (5 pM;
filled squares). TNF alone (5 pM) is
shownby the filled triangles. Theeffect
of cycloheximide (5 jig/ml) on VPF-
induced expression ofendothelial pro-
coagulant activity (endothelium was
incubated with VPF [200 pM] and cy-
cloheximide) is shown by the open tri-
angle. (Inset B) The same study as in
inset A, except purified guinea pig VPF
was used in place of murine VPF. In
each inset, incubation time (x-axis) is
plotted vs. tissue factor equivalents
(pg/106 cells; y-axis). The mean t SD
of triplicate determinations is shown.
In certain cases, where the error bars
are difficult to see, the error was smaller
than the symbol size.
was observed, and later, addition of TNF enhanced the re-
sponse. Simultaneous exposure of endothelial cells to VPF
and meth A factor together didnot enhance the procoagulant
response compared with that observed with either mediatorFigure 6 .
￿
Effect ofVPF, meth A factor, andTNF on endothelial tissue
factor . Endothelial monolayers were incubated with either murine VPF
(150 pM) alone (open bar) or in the presence ofTNF (5 pM ; hatched bar);
with meth A factor (30 pM) alone (open bar) or in the presence ofTNF
(5 pM ; hatched bar) ; or with meth A factor + murine VPF (at the same
concentrations as above) alone (open bar) or in the presence of TNF
(5pM ; hatched bar) . For these studies, endothelial cultures were preincubated
for 24 h at 37°C with VPF, and then meth A factor, in the presence or
absence ofTNF, was added for anadditional 6 h . At the end oftheincuba-
tion period, tissue factor activity was determined as described in the text .
The mean ± SD of triplicate determinations is shown .
alone, but when TNF was added in the presence of both
tumor-derived factors, the greatest tissue factor induction of
all was observed.
Stimulation ofMonocyte Procoagulant Activity by VPF .
￿
Mono-
cyte-macrophages are a recognized source ofinducible tissue
factor activity (24-26), both within the vasculature, and in
the extravascular space . This led us to examine ifVPF could
induce monocyte tissue factor. The addition of murineVPF
to monocytes led to the production of monocyte procoagulant
activity that could be blocked by neutralizing antibody to
human tissue factor (Fig . 7) . This occurred in a time-dependent
manner, and could be blocked by the simultaneous addition
of cycloheximide to cultures (data not shown) . The effect
of murine VPF on monocyte tissue factor was also depen-
dent on the concentration of mediator, being half-maximal
at -60 pM (Fig . 7) . Pre-incubation of VPF-containing
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Figure 7 .
￿
Induction ofmonocyte tissue factorby VPF. Peripheral blood
monocytes (105/assay) were incubated for 6 h at 37°C with the indicated
concentrations of murine VPF. When VPF was adsorbed from samples
with specific antibody, as in Fig. 4, VPF-mediated induction of tissue factor
was blocked (open triangle) . When antibody to tissue factor (5 jig/ml) was
incubated with monocytes (30 min at 37°C), after pre-incubation of cul-
tures with VPF for 6 h, procoagulant activity was blocked (') . The mean
t SD of triplicate determinations is shown. In certain cases, where the
error bars are difficult to see, the error was smaller than the size of
the symbol .
samples with the monospecific anti-VPF antibody linked to
a solid support blocked VPF-mediated induction ofmono-
cyte tissue factor, indicating that VPF was the active species
for the induction of tissue factor.
Stimulation of Monocyte Chemotaxis by VPF .
￿
For VPF-
stimulated monocytes to exert their effect locally, a mecha-
nism promoting their migration was required . This led us
to examine ifVPF could selectively induce monocyte migra-
tion . VPF induced migration of monocytes isolated from
human blood . Checkerboard analysis indicated that this was
Chmotaxis and not chemokinesis (Table 2) . Chemotaxis was
blocked when samples ofVPF were pre-absorbed with anti-
VPFIgG (data not shown) . In contrast to induction ofmono-
cyte migration, VPF was not a chemoattractant for human
polymorphonuclear leukocytes or lymphocytes. When en-
dothelial cells were grown to confluence on collagen mem-
Checkerboard analysis was carried out by adding the indicated concentration of murine VPF in balanced salt solution to the upper or lower well
of the chemotactic chamber, as described in the text . The positive control, consisting of the chemotactic response to FMLP (10-7 M), resulted in
40 cells per high-powered field . No VPF in the lower chamber resulted in <4 cells per high-powered field .
" Number of cells per high-powered field t SEM, n - 4.
Table
VPF
(lower
2. Checkerboard Analysis of Monocyte Chemotactic
compartment) 0 PM
Response to VPF
VPF (upper
10 PM
compartment)
30 pM 100 pM
PM
10 4.7 ± 1 .2" 4.3 ± 0.5 5.0 ± 1.6 4.0 ± 1 .2
30 8.3 t 1.2 6.0 t 0.8 5.7 t 1.6 4.5 ± 1 .4
100 27.0 t 2.9 13.0 ± 2.1 3 .3 t 0.5 3.4 t 0.8branes, and VPF was placed in the compartment below the
monolayer, it induced monocytes to cross the monolayer (Fig.
8) . In the presence of VPF, there was increased association
of monocytes with the endothelial cells, and monocytes were
observed migrating between cell-cell junctions and beneath
the endothelial monolayer (Fig. 8, A and B), compared with
controls without VPF (Fig. 8 C) . Over several experiments,
VPF appeared to induce an approximately threefold increase
in the number of monocytes migrating across endothelial
monolayers .
Discussion
In view of the potential importance of perturbations of
endothelial coagulant properties, much work has focussed
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Figure 8.
￿
Induction of monocyte migration across
endothelial cell monolayers by VPF. Confluent en-
dothelial monolayers grown on collagen membranes
were incubated with human peripheral blood mono-
cytes (106/cm2 ) for 3.5h at 37°C in the presence (A
and B) or absence (C) of VPF (100 pM) in the com-
partment beneath themonolayer. Cultures were washed
and prepared for electron microscopy as described in
the text . Monocytes (M) can be seen beneath the
endothelial (E) monolayer and also attached to the
endothelial surface. The scale bar denotes 1 lim in
each case .
on cytokines, including mediators produced by tumor cells,
and their ability to change the endothelium from a surface
promoting blood fluidity to one that could support clot forma-
tion (27-31) . In a previous study, we described a polypeptide
producedby methA sarcoma cells that induced tissue factor in
endothelium and enhanced the procoagulant response of these
cells to TNF (7) . The experiments described in the current
study demonstrate an additional, distinct polypeptide that
appears to be the murine homologue ofVPF. The present
data suggest that elaboration ofVPF bymethA sarcoma cells
can induce tissue factor production by the endothelium . VPF
has been characterized in previous studies as an agent that
increases vascular permeability, and stimulates endothelial
growth in vitro and angiogenesis in vivo (8-12). The growth-
promoting property of VPF has led to the independenttion and cloning ofa group ofproteins knownas VEGF
(8, 12). One of the cDNA variants of VEGF has the same
amino acid sequence as VPF, and the other two are smaller
versions that could arise from differential mRNA splicing
(12). Our isolation of VPF using an assay reflecting induc-
tion of tissue factor in endothelial cells represents the third
independent isolation ofthe same factor using three different
types of assays, and suggests a new and unexpected role for
VPF in the regulation of coagulation.
Since growing cells have been reported to express more
tissue factor than cells in quiescent cultures (32), it was im-
portant to determine whether VPF-mediated production of
tissue factor was secondary to induction ofcell growth. This
would not seem to be the case, however, since the experi-
ments were carried out on confluent cultures, in which there
was no increase in cell number after addition of VPF. Fur-
thermore, we have also observed in pilot studies that basic
fibroblast growth factor (bFGF), another potent mitogen for
endothelial cells(33, 34), did not induce tissue factor expres-
sion, although the characteristic change in morphology of
the monolayer reported with bFGF was observed (35). This
indicates that induction of tissue factor is a specific effect of
VPF, not of any endothelial mitogen.
When TNF was infused into mice bearing sensitive tumors,
an intense and localized vascular reaction occurred that led
to decreased tumor bloodflow and clot formation in the tumor
vasculature (3). This observation suggested that endothelial
cells in the tumor bed may have been specifically primed to
respond to the infused TNF. One mechanism that could ac-
count for this is enhancement of TNF-mediated induction
of tissue factor by tumor products such as VPF and meth
A factor. The experiments presented in Fig. 61end support
to this hypothesis. Furthermore, experiments in which en-
dothelial cells were incubated for longer times (several days)
with VPF, to mimic the in vivo situation, and then chal-
lenged with TNF, also showed an enhanced procoagulant
response to TNF. If one compares generation of endothelial
tissue factor in unfractionated tumor-conditioned medium,
it would appear that VPF and meth A factor each contribute
-50% towards the induction ofprocoagulant activity (Table
1). This is consistent with the concept that both factors con-
tribute to induction oftissue factor in the tumor vascular bed.
Although the current work has focused on induction of
procoagulant activity by VPF and TNF, the interaction of
these factors may be at least as important for altering other
endothelial properties, such as barrier function of the cell
monolayer. For example, both VPF and TNF have been
shown to increase vascular permeability, though, presumably,
by independent and potentially different mechanisms (9,
36-38). Thus, an exaggerated and rapid decrease in barrier
function ofendothelium in tumor vasculature after TNF in-
fusion could be a hemodynamically significant factor in de-
termining alterations in tumor blood flow. In termsof mech-
anisms through which VPF and TNF bring about changes
in cellular properties, we considered the possibility that VPF
couldenhance endothelial binding sites for TNF, by analogy
with studies indicating that certain mediators and induction
of the growth/migratory state in endothelium can lead to
enhancement of TNF binding (39, 40). However, pilotradio-
ligand binding studies with radioiodinated TNF did not dem-
onstrate a significant effect of VPF on the binding of TNF
to the endothelial cell surface, suggesting that VPF and TNF
may reinforce each other's actions at an intracellular site. In
this context, VPF has recently been shown to induce a rise
in endothelial cytosolic calcium (41), suggesting a possible
common locus in intracellular signal transduction mechanisms
at which TNF and VPF could act.
Solid tumors are dependent on both growth ofthe stroma
and angiogenesis (27). H. Dvorak (28) has proposed that in-
creased vascular permeability in the tumor leads to the es-
cape of plasma components, including fibrinogen, and can
promote formation of a fibrin gel that serves as a substrate
for tumor and blood vessel growth. Since endothelium has
a central role in regulating both the coagulation mechanism
and barrier function (29), we have examined the effects of
tumor-derived mediators on these properties of endothelial
cells. Alterations in these homeostatic functions are closely
linked, since activation of coagulation leads to formation of
proteases, such as thrombin and fibrin, which have been shown
to change endothelial shape and cause gaps to form between
hitherto contiguous cells, leading to increased vascular per-
meability (30, 31) . Conversely, increased permeability or
leakage of the endothelial monolayer could bringplasma pro-
teins or formed elements of the blood into contact with the
collagenous basement membrane and initiate clotting.
VPF-mediated monocyte chemotaxis and activation may
provide a mechanism explaining the presence of activated mac-
rophages in certain neoplasms. Based on our data demon-
strating that VPF can induce tissue factor and chemotaxis
in monocytes/macrophages, it is possible that VPF produced
by a tumor contributes to the in vivo observations. Although
further experiments will be required to test this hypothesis,
attraction of macrophages to the periphery of neoplastic le-
sions and their participation in formation ofa fibrin network
about the lesion could diminish access and function of im-
mune effector cells in the host response to the tumor (27,
28, 42).
These studies contribute to an emerging picture in which
the altered properties of tumor vasculature result from the
effects and interactions of tumor-derived and host response
mediators. Furthermore, they point to a potentially impor-
tant role ofVPF in the modulation of endothelial and mono-
cyte procoagulant activity, and migration of monocytes into
the tumor bed.
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